PepGen Inc
Company Profile
Business description
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
Contact
321 Harrison Avenue
8th Floor
BostonMA02118
USAT: +1 781 797-0979
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
56
Stocks News & Analysis
stocks
Strong guidance from undervalued ASX share
stocks
TSMC earnings: Refining guidance and expansion plans amid strong AI demand
stocks
Unconventional wisdom: A top performing ‘AI share’ accidently ended up in my portfolio
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,168.70 | 33.00 | 0.36% |
| CAC 40 | 8,425.13 | 162.43 | 1.97% |
| DAX 40 | 24,702.24 | 547.77 | 2.27% |
| Dow JONES (US) | 49,594.21 | 1,015.49 | 2.09% |
| FTSE 100 | 10,667.63 | 77.64 | 0.73% |
| HKSE | 26,160.33 | 233.93 | -0.89% |
| NASDAQ | 24,480.69 | 377.98 | 1.57% |
| Nikkei 225 | 58,475.90 | 1,042.44 | -1.75% |
| NZX 50 Index | 12,905.67 | 160.39 | -1.23% |
| S&P 500 | 7,136.51 | 95.23 | 1.35% |
| S&P/ASX 200 | 8,946.90 | 36.80 | 0.41% |
| SSE Composite Index | 4,051.43 | 4.12 | -0.10% |